Rajesh is a scientific key opinion leader with 25+ years in drug development, specializing in model-informed strategies for biologics, vaccines, and small molecules. Currently a Senior Distinguished Scientist at Certara, he leads strategic consulting and the CDDS centers of excellence. Previously, he founded Merck’s quantitative clinical pharmacology department and held key roles at Aventis and Bristol-Myers Squibb. Rajesh holds a PhD in Pharmaceutical Sciences (University of British Columbia) and an MBA in Strategy and Innovation (Warwick). Consistently recognized among the top 2% of influential scientists, his work includes 100+ publications, 89 posters, and 4 books. He is an elected fellow of AAPS.
Rajesh Krishna, PhD
Senior Distinguished Scientist, Drug Development Solutions

More resources by Rajesh Krishna, PhD
细胞疗法开发的主要考虑因素
博客
临床药理学与定量药理学为何要合作
博客
Resmetirom: A pioneering NASH clinical program
博客
临床开发计划如何帮助药物项目?
博客
对 FDA 新抗体-药物偶联物临床药理指南的思考
博客
什么是生物仿制药及其开发方法?
博客
了解发现资产目标产品简介的作用
博客
在罕见病药物研发中提高信号发现率的方法
博客
如果你的新分子实体没有明确的药物效应,请停止!
博客
Drug Development Considerations for Live Biotherapeutic Products
博客
人工智能:它是什么,以及它如何加速罕见病药物开发?
博客
为何应在开始临床研究前选择药物制剂
博客
为什么人体放射性标记质量平衡研究在临床药理学和药物开发中非常重要?
博客
为什么 FDA 关于循环肿瘤 DNA 的新指南对肿瘤早期临床药物开发至关重要
博客
Reflections on the Recent ICH E11A Pediatric Extrapolation Guideline
博客
罕见病药物开发模型的实用性
博客
如何纠正生物等效性评估中的重大误区
博客
专家解读生物等效性 5 大误区
博客
不要忘记安全!如何在早期临床开发中评估候选药物的安全性
博客
A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease
博客
开发靶向共价抑制剂药物:3关键考虑因素
博客
临床药理学顾问的日常一天
博客
Building a Robust Clinical Pharmacology & Model-Informed Drug Development Strategy for New Alzheimer’s Disease Drugs
博客
确保抗体-药物偶联物开发最大概率获得成功的关键考虑事项
博客